Trevena, Inc.

Trevena, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative medicines for central nervous system disorders. The company's lead product candidates include OLINVYK (Oliceridine) injection for managing moderate-to-severe acute pain, TRV027 for treating acute lung injury and abnormal blood clotting in COVID-19 patients, TRV250 for acute migraine, TRV734 for moderate-to-severe acute and chronic pain, and TRV045 for chronic pain management. Trevena, Inc. generates revenue through the development and potential commercialization of these novel medicines, with a focus on addressing unmet medical needs in the central nervous system disorder space.

Products

• OLINVYK (Oliceridine) injection

• TRV027

• TRV250

• TRV734

• TRV045